Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company

Source: Nasdaq GlobeNewswire / 25 Jul 2024 22:00:00   America/Los_Angeles

Dear shareholder,

Dear Madam, Dear Sir,

please find attached our press release.

Best regards

Ackermans & van Haaren

Attachment

• Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics (press release 26 July 2024)